The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. This year’s metric has recorded a Price increase of 55.58%. However, over the past six months, we’ve seen a weaker performance of 146.54%. The price of TRVI leaped by -2.88% over the last 30 days. And in the last five days, it has surged by 1.50%.
Trevi Therapeutics Inc saw a rather consistency, in terms of market performance. The company’s stock reached its highest point at $7.48 on 06/02/25, while the lowest price for the same duration was marked at $2.30 on 06/10/24.
52-week price history of TRVI Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Trevi Therapeutics Inc’s current trading price is -14.30% away from its 52-week high, while its distance from the 52-week low is 178.70%. The stock’s price range during this period has varied between$2.30 and $7.48. The Trevi Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 2.58 million for the day, a figure considerably lower than their average daily volume of 2.66 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Trevi Therapeutics Inc (TRVI) has experienced a quarterly rise of 5.60% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 763.72M and boasts a workforce of 26 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
TRVI’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for TRVI stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.01.
